These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 8644848)

  • 1. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
    Brown LF; Tognazzi K; Dvorak HF; Harrist TJ
    Am J Pathol; 1996 Apr; 148(4):1065-74. PubMed ID: 8644848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma.
    Skobe M; Brown LF; Tognazzi K; Ganju RK; Dezube BJ; Alitalo K; Detmar M
    J Invest Dermatol; 1999 Dec; 113(6):1047-53. PubMed ID: 10594750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.
    Brown LF; Berse B; Jackman RW; Tognazzi K; Guidi AJ; Dvorak HF; Senger DR; Connolly JL; Schnitt SJ
    Hum Pathol; 1995 Jan; 26(1):86-91. PubMed ID: 7821921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
    Brown LF; Berse B; Jackman RW; Tognazzi K; Manseau EJ; Senger DR; Dvorak HF
    Cancer Res; 1993 Oct; 53(19):4727-35. PubMed ID: 8402650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma.
    Guidi AJ; Abu-Jawdeh G; Tognazzi K; Dvorak HF; Brown LF
    Cancer; 1996 Aug; 78(3):454-60. PubMed ID: 8697391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
    Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B
    Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia.
    Denhart BC; Guidi AJ; Tognazzi K; Dvorak HF; Brown LF
    Lab Invest; 1997 Dec; 77(6):659-64. PubMed ID: 9426404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor.
    Brown LF; Detmar M; Tognazzi K; Abu-Jawdeh G; Iruela-Arispe ML
    Lab Invest; 1997 Feb; 76(2):245-55. PubMed ID: 9042161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental expression of vascular endothelial growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes.
    Bogic LV; Brace RA; Cheung CY
    Placenta; 2001 Apr; 22(4):265-75. PubMed ID: 11286562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology.
    Morini M; Benelli R; Giunciuglio D; Carlone S; Arena G; Noonan DM; Albini A
    Biochem Biophys Res Commun; 2000 Jun; 273(1):267-71. PubMed ID: 10873597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
    Arbiser JL; Larsson H; Claesson-Welsh L; Bai X; LaMontagne K; Weiss SW; Soker S; Flynn E; Brown LF
    Am J Pathol; 2000 Apr; 156(4):1469-76. PubMed ID: 10751370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression.
    Brogi E; Schatteman G; Wu T; Kim EA; Varticovski L; Keyt B; Isner JM
    J Clin Invest; 1996 Jan; 97(2):469-76. PubMed ID: 8567969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
    Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
    Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.
    Brown LF; Berse B; Jackman RW; Tognazzi K; Manseau EJ; Dvorak HF; Senger DR
    Am J Pathol; 1993 Nov; 143(5):1255-62. PubMed ID: 8238242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.
    Straume O; Akslen LA
    Am J Pathol; 2001 Jul; 159(1):223-35. PubMed ID: 11438469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
    Brown LF; Olbricht SM; Berse B; Jackman RW; Matsueda G; Tognazzi KA; Manseau EJ; Dvorak HF; Van de Water L
    J Immunol; 1995 Mar; 154(6):2801-7. PubMed ID: 7876550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.
    Fava RA; Olsen NJ; Spencer-Green G; Yeo KT; Yeo TK; Berse B; Jackman RW; Senger DR; Dvorak HF; Brown LF
    J Exp Med; 1994 Jul; 180(1):341-6. PubMed ID: 8006592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.